The Indian Council of Medical Research (ICMR) is funding a study to determine if a drug called colchicine can be used to treat the symptoms of Covid-19.
Colchicine is commonly used to treat gout, as well as inflammation and pain.
While the ICMR is funding the study, the George Institute for Global Health will conduct the clinical trials and provide the data to the ICMR.
Long-term symptoms of Covid are usually weakness, fatigue, headache, memory disturbances, sleep disturbances, persistent cough, shortness of breath, depression or anxiety, chest pain, palpitations, nausea, diarrhea, intermittent fever, changes in the ability to taste or smell, dizziness or lightheadedness, and muscle or joint pain.
A brochure shared by the George Institute for Global Health is seeking volunteers – those experiencing prolonged symptoms after Covid – for clinical trials aimed at determining the efficacy of colchicine in preventing or reducing symptoms.
The trial is being carried out in 10 hospitals: four in Maharashtra (three in Pune and one in Aurangabad), two in Kerala (Kochi and Wayanad), and one each in Karnataka (Manipal), Gujarat (Anand), Andhra Pradesh (Guntur ) and Rajasthan (Jaipur).
The George Institute of Global Health is based in Australia with offices in India, China, and the UK.
“This study is led by the George Institute for Global Health and funded by the ICMR,” said a senior ICMR official. Work line.
Work is underway globally to determine which drugs can be used to treat long-term Covid.
Selection of volunteers
For the trial, 350 volunteers over 18 years of age and with a previous laboratory-confirmed diagnosis of Covid will be selected through eligibility tests.
The results of the 52-week trial will be presented to the ICMR, according to information from the George Institute for Global Health.
Following blood tests and spirometry tests, participants will receive colchicine at selected doses and over a period of time.
The volunteers will have to undergo regular check-ups at week 12, at week 22, and so on.
File image | Photo Credit: fairywong